KALA BIO Inc. Common Stock (KALA)

About KALA

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation envir…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

6

Website

www.kalarx.com/

Fundamentals

1-day range

$0.5867$1.09

Market cap

$14.25M

P/E (trailing)

—

P/E (forward)

-0.10

EPS (trailing)

$-136.77

Dividend yield

—

Beta

-2.63

Avg. volume

134.1K

KALA BIO Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KALA

  KALA BIO Inc. Common Stock

  $0.6949

  ▼ 14.42%
  Market cap $14.25MP/E —
  $0.5867$1,030
• COCP

  Cocrystal Pharma Inc. Common Stock

  $1.11

  ▼ 2.63%
  Market cap $14.20MP/E —
  $0.76$2.67
• AKTX

  Akari Therapeutics plc ADS

  $11.03

  ▲ 22.42%
  Market cap $14.14MP/E Infinity
  $3.02$49.6
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.00MP/E 85.09
  $5.61$31
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $13.80MP/E —
  $0.1772$1.45
• KTTA

  Pasithea Therapeutics Corp. Common Stock

  $0.5975

  ▲ 7.66%
  Market cap $14.82MP/E —
  $0.281$2.06
• HIND

  Vyome Holdings Inc. Common Stock

  $2.2

  ▼ 0.23%
  Market cap $15.02MP/E —
  $1.75$12.87

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Kala Bio Q2 EPS $(21.32) Up From $(85.64) YoY, Sales $0.00, Same YoY
  benzinga · 8/19/2026
• Kala Bio Q2 EPS $(21.32) Up From $(85.64) YoY, Sales $0.00, Same YoY
  Benzinga · 8/19/2026